We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Kymera Therapeutics, Inc. (KYMR) Soars 14.3%: Is Further Upside Left in the Stock?
Read MoreHide Full Article
Kymera Therapeutics, Inc. (KYMR - Free Report) shares ended the last trading session 14.3% higher at $15.51. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 31.7% loss over the past four weeks.
The surge in the stock price is likely to be an outcome of the positive momentum built around the company's pipeline. Its lead pipeline candidate, IRAK-4 is being developed in early-to-mid stage studies, to treat multiple autoimmune disorders.
This company is expected to post quarterly loss of $0.73 per share in its upcoming report, which represents a year-over-year change of +7.6%. Revenues are expected to be $20.98 million, up 119.7% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Kymera Therapeutics, Inc., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on KYMR going forward to see if this recent jump can turn into more strength down the road.
Kymera Therapeutics, Inc. belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Vaccitech PLC Sponsored ADR , closed the last trading session 18.1% higher at $3.79. Over the past month, VACC has returned 57.4%.
Vaccitech PLC Sponsored ADR's consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.62. Compared to the company's year-ago EPS, this represents a change of -381.8%. Vaccitech PLC Sponsored ADR currently boasts a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Kymera Therapeutics, Inc. (KYMR) Soars 14.3%: Is Further Upside Left in the Stock?
Kymera Therapeutics, Inc. (KYMR - Free Report) shares ended the last trading session 14.3% higher at $15.51. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 31.7% loss over the past four weeks.
The surge in the stock price is likely to be an outcome of the positive momentum built around the company's pipeline. Its lead pipeline candidate, IRAK-4 is being developed in early-to-mid stage studies, to treat multiple autoimmune disorders.
This company is expected to post quarterly loss of $0.73 per share in its upcoming report, which represents a year-over-year change of +7.6%. Revenues are expected to be $20.98 million, up 119.7% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Kymera Therapeutics, Inc., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on KYMR going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Kymera Therapeutics, Inc. belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Vaccitech PLC Sponsored ADR , closed the last trading session 18.1% higher at $3.79. Over the past month, VACC has returned 57.4%.
Vaccitech PLC Sponsored ADR's consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.62. Compared to the company's year-ago EPS, this represents a change of -381.8%. Vaccitech PLC Sponsored ADR currently boasts a Zacks Rank of #3 (Hold).